Cytotoxicity testing is an in vitro biological evaluation that assesses whether a medical device, a material, or an extract of either can cause harmful effects in cultured mammalian cells, such as cell death, inhibited growth, or changes in cell morphology. It is one of the biological endpoints most commonly considered for devices that contact the body, and it is typically one of the first screens applied to materials during development. For medical device developers moving from prototype to regulatory submission, understanding what the test measures, how it fits into biological evaluation, and where its limits lie helps avoid late-stage surprises.
Cytotoxicity testing is not a stand-alone safety determination. Under ISO 10993-1, it is one input into a biological evaluation conducted within a risk management process, as described in ISO 14971. This article focuses on cytotoxicity methods, interpretation, and how results relate to material and manufacturing choices. For broader context on skin irritation, sensitization, and overall material evaluation for skin-contact products, see the complete guide to biocompatibility in wearable medical devices.
How cytotoxicity testing fits into biological evaluation
Biological evaluation is the structured process of assessing whether a medical device, or the materials it is made from, poses an unacceptable biological risk to patients or users. ISO 10993-1 describes the framework for planning this evaluation within a risk management process. It considers the nature and duration of body contact, the materials and manufacturing processes involved, and the biological endpoints that may be relevant to the finished device. Current guidance from regulators, including the FDA’s guidance on the use of ISO 10993-1, also expects the evaluation to be based on the final finished device, including any sterilization the device undergoes. Because the ISO 10993-1 edition and any regional recognition status change over time, manufacturers should confirm the edition applicable to their submission and market.
Within this framework, cytotoxicity testing acts as an early-stage screen. It is conducted in vitro, meaning outside a living organism, using cell cultures under controlled laboratory conditions. It is relatively fast and inexpensive compared with in vivo studies, which is why it is frequently performed early in development. A material that causes a cytotoxic response often needs investigation, and possibly reformulation, process changes, or substitution, before the evaluation of other endpoints becomes meaningful.
Regulators and notified bodies review cytotoxicity data as part of the broader biological risk assessment. The test does not stand in for that assessment. A non-cytotoxic result addresses one endpoint only, while a cytotoxic result is a significant finding that calls for root-cause analysis and a documented response.
Cytotoxicity compared with other biological endpoints
Cytotoxicity is sometimes confused with other biological endpoints. Each addresses a different question and uses a different type of test system:
- Cytotoxicity: Does the device or its extract damage or inhibit the growth of cultured cells? It is assessed in vitro, and the standard method reference is ISO 10993-5.
- Irritation: Does the device cause a localized inflammatory response in tissue? ISO 10993-23 addresses irritation testing, which may include in vitro approaches for some materials as well as in vivo methods.
- Sensitization: Can repeated or prolonged exposure trigger an allergic, immune-mediated response? ISO 10993-10 addresses this endpoint.
- Systemic toxicity, genotoxicity, and others: These endpoints address effects beyond the contact site or effects on genetic material, and are considered when the contact type, duration, and risk assessment indicate they are relevant.
Because these endpoints measure different biological responses, a favorable cytotoxicity outcome cannot be used to infer anything about irritation or sensitization potential. A material can be non-cytotoxic in cell culture and still cause skin sensitization in some users, which is a well-known concern for adhesives and other skin-contact materials.
ISO 10993-5 and common test approaches
ISO 10993-5 describes methods for evaluating the in vitro cytotoxicity of medical devices and their materials. In general terms, it covers extract-based testing, direct contact testing, and indirect contact testing, along with considerations for cell lines, controls, and the assessment of results. The specific method, test conditions, and cell system should be selected and justified based on the device, its materials, and the intended contact. Developers should consult the current published standard for requirements, as this article only summarizes the concepts.
Extract test
In the extract method, the test material is incubated in a suitable extraction vehicle, such as cell culture medium, under defined conditions of surface area or mass per volume, time, and temperature. The resulting extract is then applied to cultured cells. This approach is widely used for materials that may release leachable substances, including adhesives, inks, coatings, and polymers containing additives. Its relevance depends on how well the extraction conditions represent the substances that could realistically be released in use.
Direct contact test
In the direct contact method, the test material is placed in contact with a layer of cultured cells, and the cells near and beneath the material are examined for changes. It can be suitable for solid materials and certain device components, and it can reveal effects at the material surface. It may be less appropriate for materials that are very dense, absorptive, or physically disruptive to the cell layer, where the observed effect may not reflect chemical toxicity.
Indirect contact test
Indirect contact methods place a barrier, such as an agar layer or a filter, between the test material and the cells, so that any effect depends on substances diffusing through the barrier. Agar diffusion is the best-known example. It can be useful for certain material forms but may be less sensitive to some leachables, such as substances that do not diffuse readily through the barrier.
Comparing the approaches
| Approach | How it works | What it assesses | Key limitations |
|---|---|---|---|
| Extract test | Material is extracted in a vehicle; extract is applied to cell cultures | Effects of leachable substances on cell viability and morphology | Result depends on extraction conditions; may not capture surface-contact effects |
| Direct contact test | Material is placed in contact with a cell layer | Local effects of the material surface and releasable substances on adjacent cells | Physical effects such as pressure or movement may confound results; not suited to all material forms |
| Indirect contact test | A barrier such as agar separates material and cells; substances diffuse through | Effects of diffusible substances on cells | May be less sensitive to leachables that do not diffuse through the barrier |
No single approach is universally appropriate. Method selection should follow from the material form, expected leachables, intended contact, and the rationale documented in the biological evaluation plan.
Cell viability, morphology, controls, and interpretation
Cytotoxicity results are based on how cells respond after exposure. Two kinds of observation are common. Qualitative assessment examines cell morphology under a microscope for signs such as rounding, detachment, vacuolization, or lysis, and may assign a reactivity grade. Quantitative assessment measures cell viability, often through colorimetric assays that reflect metabolic activity, and compares exposed cells with controls. ISO 10993-5 describes both kinds of assessment, and the choice depends on the method and the laboratory’s validated procedures.
Controls are central to interpretation. A negative control establishes the baseline response of healthy cells, and a positive control confirms the test system can detect a cytotoxic effect. Blank controls account for the effect of the extraction vehicle or test setup. Without valid controls, a result cannot be reliably interpreted.
Acceptance and interpretation criteria depend on the method and on how the laboratory and the manufacturer define them in the test protocol and evaluation plan, so this article does not state numeric thresholds. Results close to a limit, or results that differ between methods, typically call for further investigation rather than a simple pass or fail conclusion. A cytotoxic response can also arise from factors unrelated to the material itself, such as extraction conditions, residues from manufacturing, or physical interference with the cell layer, so laboratory reports should be reviewed with these possibilities in mind.
When cytotoxicity testing may be relevant
Cytotoxicity is among the endpoints that ISO 10993-1 and regulatory guidance commonly treat as relevant across many categories of body contact, from intact skin contact to implants. Whether and how a given device needs cytotoxicity data depends on its contact nature and duration, its materials, its manufacturing and sterilization processes, and the available characterization data. It is not accurate to say that every device must undergo identical testing.
Where existing data on a material or a predicate device is available, a manufacturer may be able to justify using it in place of new testing, but the justification must be documented in the biological evaluation. The decision rests with the manufacturer, supported by qualified regulatory and toxicological expertise.
Changes can also reopen the question. New formulations, new material combinations, changes to manufacturing processes, cleaning steps, or sterilization methods may alter what a device releases and can prompt a reassessment of the biological evaluation, including cytotoxicity, even for a previously evaluated device.
How materials and processes affect results
Cytotoxicity outcomes reflect the finished material as manufactured, not only its base composition. Several factors can influence what is released into an extract or onto a cell layer:
- Material composition: Residual monomers, plasticizers, stabilizers, colorants, and processing aids in polymers, foams, and films may be released.
- Adhesives and hydrogels: Residual reactants, cross-linking agents, preservatives, and other formulation components can leach and affect cells.
- Coatings and printed layers: Inks, binders, solvents, and conductive particles may release substances, and incomplete curing or drying can increase residuals.
- Manufacturing processes: Curing conditions, lamination, die cutting, and handling can leave residues or alter the surface.
- Cleaning: Cleaning agents and incomplete removal of process residues can contribute to a cytotoxic response, while effective cleaning may reduce it.
- Sterilization, where applicable: Sterilization processes, including ethylene oxide, can leave residuals or modify materials, which is one reason evaluation of the finished, sterilized device is generally expected.
Because of these factors, results obtained on a raw material do not automatically transfer to a finished component made with a different process or in a different configuration.
Relevance to electrodes, hydrogels, flexible substrates, and wearables
Skin-contact wearables and medical electrodes combine several materials in close contact with skin, often for extended wear. Typical elements include flexible polymer substrates, conductive inks or layers, adhesives, and conductive hydrogels. Each of these can contribute leachable substances, and the interaction of materials in a laminated construction can matter as much as any individual component.
Cytotoxicity testing may therefore be considered for the finished electrode or for representative components, depending on the biological evaluation plan. Hydrogels and adhesives often receive particular attention because of their formulation chemistry, and printed conductive layers are examined for residual solvents and binder components. For a deeper look at how conductive material choices relate to biocompatibility, see the guide to biocompatible conductive materials for medical electrodes. For product-specific context, see Screentec’s ECG electrode segment.
Why a cytotoxicity result is not proof of safety or conformity
A favorable cytotoxicity result shows that, under the specific test conditions used, the tested extract or material did not produce a cytotoxic response in the chosen cell system. It does not establish that the finished device is biologically safe, that other endpoints such as sensitization or irritation have been addressed, or that the device conforms to regulatory requirements.
In vitro cell culture also has inherent limits. It does not reproduce the full complexity of living tissue, immune responses, or long-term wear conditions, and its sensitivity varies with the method and the substances involved. For these reasons, cytotoxicity data should be interpreted within the full biological evaluation, alongside material characterization, risk assessment, and any additional endpoint testing the evaluation calls for. Passing a cytotoxicity test does not constitute regulatory approval or clearance, which depends on the manufacturer’s complete submission and the review of the relevant authority.
Working with a CDMO on material decisions
Cytotoxicity testing itself is performed by qualified biological safety laboratories selected by the device manufacturer, and responsibility for the biological evaluation, design controls, clinical safety, and regulatory approval of the final device remains with the manufacturer. Material and process choices made during development nonetheless influence what a device releases and how much characterization it needs.
Screentec is a Finnish contract development and manufacturing organization (CDMO), certified to ISO 13485 and ISO 9001, that manufactures customer-defined medical electrodes, wearable sensors, and specialized electronic components. Screentec does not operate a cytotoxicity testing laboratory or provide regulatory consulting, and it does not guarantee the biocompatibility of customer devices. What a manufacturing partner can contribute is process control and documentation aligned with ISO 13485 quality requirements, along with practical input on material selection and manufacturability, so that customers can build their biological evaluation on well-defined, consistently produced materials.
For teams developing custom skin-contact electrodes, R&D and prototyping support focused on material and process choices can help clarify construction details early, before samples are submitted for testing.
If you are planning a custom skin-contact medical electrode product, you are welcome to discuss material selection and manufacturing feasibility with Screentec’s team.
This content was generated with the help of AI and it may contain mistakes